Introduction
============

Critical medical situations can occur in space missions ^[@ref-1]^. In such situations, adequate treatment may require the use of drugs with potential severe side effects. Pharmacokinetics and pharmacodynamics can be modified under weightlessness conditions by many factors ^[@ref-2],\ [@ref-3]^, which may lead to undesired pharmacological effects. These parameters should be assessed carefully in order to ensure safe use of medications in space. However, insufficient information exists in this regard in microgravity ^[@ref-4],\ [@ref-5]^ and proper empirical evaluation is not feasible due to the significant associated risks.

ABC (ATP-Binding Cassette) transporters are a large family of trans-membrane proteins widely present in many life forms, from bacteria to mammals. In humans, they play important roles in many physiological processes and in drug pharmacokinetics, pharmacodynamics, and drug-to-drug interactions of many currently used medications in oncology, emergency medicine, critical care and general practice ^[@ref-6],\ [@ref-7]^. Inhibition of these transporters has been correlated with clinically relevant metabolic disorders, drug overdosing, and drug toxicity ^[@ref-7]^. On the other hand, their overexpression can lead to treatment failure due to enhanced drug cell clearance and increased drug excretion from the body ^[@ref-7]^. Multi-drug resistance-associated protein 2 (MRP2) is a well-studied representative of the ABC transporters family, by which transport of glucuronide, sulphate and gluthatione-conjugated drugs is made against a concentration gradient requiring adenosine-tri-phosphate (ATP) hydrolysis ^[@ref-8]^.

Genetic expression of ABC transporters has been found to change in real and simulated microgravity conditions. Two independent studies evaluated gene expression pattern in two models of medically relevant species of microorganisms ( *Salmonella* sp. and *Candida* sp.) and found upregulation of certain ABC transporters genes during short duration spaceflight missions ^[@ref-9],\ [@ref-10]^. Similarly, results from a microgravity simulation study showed that significant variation of certain ABC transporter levels could be found in the liver and kidneys of a murine model ^[@ref-11]^. These changes could lead to a modified antimicrobial susceptibility in microgravity and to different pharmacokinetic characteristics of medications during spaceflight. Furthermore, recent reports suggest that microgravity can modify the activity of certain important cell components ^[@ref-12]--\ [@ref-14]^, especially transmembrane proteins and ion channels ^[@ref-15]--\ [@ref-17]^ with structural and functional similarities to ABC transporters. Changes in ABC transporters activity could lead to clinically significant metabolic disorders and potentially dangerous undesired pharmacological effects during spaceflight. However, there is no current technology that permits a functional evaluation of these cellular components in microgravity. Therefore, we developed a new approach combining the use of a currently available commercial assay, a high precision electromechanical system and an enhanced drug detection protocol to evaluate ABC transporters activity in microgravity conditions. A validation study of this new biotechnological approach is presented.

Glossary
========

[Microgravity:]{.ul} A condition in which there is very little net gravitational force, as of a free-falling object, an orbit, or interstellar space. In this text microgravity, weightlessness and zero gravity (0g) are considered equivalents.

[Parabolic flight/parabolic flight campaign:]{.ul} To create a weightless environment, an especially prepared airplane flies in a long parabolic arc, in which two 2g periods are experienced while ascending (injection phase) and recovering (pull out phase) from the manoeuvre. In between these two periods, the aircraft enters into a free falling state, lasting approximately 22s, in which microgravity is obtained inside the cabin. A regular parabolic flight consists of 30 parabolas with a number of breaks. A parabolic flight campaign consists of three flights.

Methods
=======

This study was performed during the 51 ^st^ European Space Agency (ESA) parabolic flight campaign, under the auspices of the "Fly your thesis" programme, and was developed following the specifications and experimental requirements of ESA/Novespace parabolic flight campaigns ^[@ref-18]^.

Samples and procedures
----------------------

A modified, validated and commercial Vesicular Transport Assay ^®^ (Solvo Biotechnology, Hungary) was used to evaluate MRP2 transport activity of estradiol 17-β-glucuronide (E17βG) in microgravity during parabolic flights. A short overview of this assay is provided hereinafter and additional information can be found at the producer's website ( [www.solvo.hu](http://www.solvo.hu)). Recombinant baculovirus infected insect cells (Sf9 cells) are used to produce microscopic vesicles containing at least 12--15% of the selected human transporter protein following a standardized and validated production protocol owned by the producer ^[@ref-7]^. Vesicles are built allowing transport towards the interior of the vesicle. Once a reaction is triggered, the substrate (E17βG) is transported into vesicles and retained. Vesicles are filtrated using a fiberglass Milipore filter (\< 1μm pore size) and eluted with pure methanol to retrieve substrate, which is later analysed. In the Vesicular Transport Assay ^®^, a base sample suspension is produced containing selected vesicles (50 μg of pure MRP2 transporter per sample) and an assay mix composed by E17βG, co-transporters and ions. Concentrations of the assay mix and vesicle quantities followed the instructions contained in the protocol provided by the vesicle producer, however volumes were adjusted to adapt to minimum volume requirements of our automated electromechanical system and to reduce the error induced by mechanical actuators. By modifying the aforementioned base suspension, four different groups of samples were generated to evaluate four different assay conditions as recommended by the producer ^[@ref-19]^. MRP2+ samples, containing a fully functional MRP2 transporter, were generated in order to evaluate the full transport capabilities of the transporter. NoATP samples were generated by using the same composition of MRP2+ samples but an ATP-free solution was injected instead at the moment of reaction start. These groups of samples permitted the evaluation of ATP-independent transport activity, known to be present in the ABC transporters family. Following vesicle producer recommendations, we also generated an additional group of samples to which benzbromarone 7.5 mM (BZM - specific non-competitive inhibitor) was added. In this set of samples, pharmacological inhibition capabilities in microgravity could be assessed. Finally, MRPdef negative control samples were generated from vesicles with mutated MRP-like transporters. These vesicles are provided by the producer and present no active transport capabilities. Therefore, they permit evaluation of simple diffusion of substrate across membranes. These samples were used as negative controls for transporter activity measurements (see supplementary material [*Appendix 1. Chemical products*](#A1){ref-type="other"} for a more detailed sample composition description). Confirmation of transporter activation requires the detection of net E17βG quantities in activated samples (MRP2+, noATP and BZM samples). Therefore, the signal from MRPdef samples was subtracted from the actual signal in each group of samples to obtain net transport activity. We performed a preliminary evaluation of the assay, which showed fast initial reaction speeds with most of E17βG being transported within few seconds. Samples were prepared in small syringes (Becton, Dickinson and Company, New Jersey, USA) containing 360 μl of the assay suspension (vesicles + assay mix), frozen immediately at -80°C and transported in dry ice to the parabolic flight campaign site. During the parabolic flight, the samples were kept in certified cold containers at 2--6°C before being used. The first five parabolas of each flight were excluded in order for the investigator to acclimatize to microgravity. The reaction was manually triggered 1s after the 6 ^th^ parabola injection phase by a precise servo-mechanic injection of 250 μl 0.2M ATP mix or ATP-free buffer depending on the sample group (MRP2+, BZM and MRPdef samples vs. noATP samples). The reaction was stopped automatically inducing a drastic temperature reduction and substrate dilution by applying 1.5 ml of washing mix at 2--6°C after 19s, still in microgravity. This procedure was repeated identically for each parabolic manoeuvre. Washing mix composition followed standard protocol specifications by the vesicle producer but volumes were adjusted to adapt to minimum volume requirements of our automated electromechanical system and to reduce the error induced by mechanical actuators. E17βG-filled vesicles were recovered by Millipore fibreglass filtration. Once on ground, pure methanol elution was performed for E17βG recovery and stabilization before transport. Standard *Escherichia coli* glucuronidase enzymatic reaction was later required for glucuronide removal from estradiol. Final estradiol concentration was measured by gas chromatography coupled to a mass spectrometry detection system (6890-GC/5973-MSD, Agilent Technologies, California, USA) using a validated methodology ^[@ref-20]^. Reference experiments were repeated on ground in 1g conditions using the same equipment, materials and procedures as those used during parabolic flights. The time lapse between sample stabilization with methanol and analysis was comparable in both cases. Sample analysis was performed using the same laboratory equipment and procedures. Results from 1g on ground reference experiments were compared with those obtained in microgravity conditions.

In order to evaluate vesicle microscopic structural integrity after gravitational stress, vesicles were exposed to 2g centrifugal forces in 60 consecutive 30s periods simulating a parabolic flight. Vesicles were compared to non-centrifuged controls at 200× under methylene blue tincture by experienced anatomo-pathologists (Pathology Department, Corporació Sanitària Universitària Parc Taulí. Sabadell, Spain). Qualitative analysis of shape and mean size estimation of vesicles was performed by experienced anathomo-pathologists, as well as a semi-quantitative vesicle number estimation using multiple 1 mm ^2^ sector partial counting method.

Equipment
---------

An electro-mechanical engineering system was especially designed to undertake the required procedures in microgravity following the design and safety specifications for parabolic flights ( [Figure 1](#f1){ref-type="fig"} & [Figure 2](#f2){ref-type="fig"}). Four experimentation units composed the prototype, one per each specific group of samples. Accurate fluid displacement was achieved implementing high precision component manufacturing and accurate linear engines (Schneider Electric, France). These engines presented 0.05 mm of displacement error, which represented a calculated 16 μl fluid displacement error (\< 10% in our experimental setup). Sample temperature was strictly controlled using a dedicated thermal control system, which consisted of four preheating chambers to raise the sample temperature from 2--6°C to 37°C and four reaction chambers to maintain the temperature at 37.3°C during the reaction. In order to protect the vesicle integrity, 45°C was established as the maximum permissible temperature at syringe wall in preheating chambers given syringe radius and its thermal conductivity. Several temperature probes feedback a central computer, which maintained the temperatures at the required levels (Minco, Minneapolis, USA; TC-Direct, Madrid, Spain). This system also enabled cold storage of ATP and washing mix at 2--6°C in two certified isothermal boxes (Tecnisample, Barcelona, Spain). All procedures were controlled by an electrical and control system, which provided electrical power, actuator control, synchronization, monitoring, logging and a user-friendly interface (Telemecanique, France) (see supplementary material [*Appendix 2. List of Components*](#A2){ref-type="other"} for a more detailed description of equipment and components used).

![Main experimental rack.\
The designed electromechanical system was composed of three racks. In this figure a scheme of the main rack is presented, containing the four experimentation units. One of the four experimentation units is highlighted with a dashed line. Several electrical holes permitted connection to all electrical components in the main rack (sensors, actuators, linear engines, resistances). One ATP-WB hole permitted access to liquid conductions transporting ATP and Wash Buffer to each experimentation units. Lengths are expressed in mm.](f1000research-3-5243-g0000){#f1}

![Final prototype configuration.\
This picture shows the final configuration of the experiment on board the parabolic aircraft. The three racks presented were, from left to right: storage rack, main rack, fluids and control rack. All principal electric components were placed in a sealed fire-proof cabinet underneath the main rack to protect the equipment from water contact in case of failure of the containment system.](f1000research-3-5243-g0001){#f2}

Statistical analysis
--------------------

Results were analysed using SPSS v19.0 (International Business Machines, New York, United States of America). ANOVA test for multiple variable comparisons was performed to confirm differences in raw E17βG signal between the four sample groups in each gravitational condition. Bilateral Dunnett t post-hoc test was later used for comparing sample groups with MRPdef controls to confirm transporter activation. Provided equality of variances could not be assured and unbalanced size of groups being compared, non-parametric Mann-Witney U test was used to evaluate the differences between microgravity and 1g on ground samples. Statistical significance threshold was established at *p* \< 0.05 bilaterally in all cases.

Results
=======

All four different assays presented expected E17βG signal profile in microgravity and on ground 1g conditions ( [Table 1](#T1){ref-type="table"}), being MRP2+ samples the most active and MRPdef the less active group of samples in all gravitational conditions. The ANOVA test revealed statistically significant signal differences between sample groups in each gravitational condition (on ground F = 4.95, *p* = 0.005 and microgravity F = 13.45, *p* \< 0.001) and post-hoc Dunnett t test confirmed statistically significant differences between MRP2+ and MRPdef in both microgravity and 1g conditions ( [Table 2](#T2){ref-type="table"}). These results confirmed activation of the transporter in MRP2+ samples. MRP2 net transport activity of 1g on ground samples laid within commercial transport standards (4.61 ng in a range of 3.7 -- 7.4 ng of E17βG in our experimental configuration), conversely microgravity samples suffered a 19-fold activity reduction with statistically significant differences of E17βG transported in all cases. The Mean activity differences between microgravity and 1g on ground samples were 10.3 ng of E17βG in MRP2+ samples (Mann-Witney U \< 0.001; *p* \< 0.001; CI 95% = 7.4 -- 13.2 ng E17βG), 5.95 ng of E17βG in MRPdef samples (Mann-Witney U \< 0.001; *p* \< 0.001; CI 95% = 4 -- 7.9 ng E17βG), 7.65 ng of E17βG in noATP samples (Mann-Witney U \< 0.001; p \< 0.001; CI 95% = 6.14 -- 9.16 ng E17βG) and 9.12 ng of E17βG in BZM samples (Mann-Witney U \< 0.001; *p* \< 0.001; CI 95% = 7.9 -- 10.3 ng E17βG).

###### Detected E17βG signal in microgravity and 1g conditions.

                 Sample   n      Mean\*   SD     \% ^†^
  -------------- -------- ------ -------- ------ --------
  microgravity   MRP2+    26     0.49     0.17   100
  MRPdef         31       0.25   0.12     51     
  noATP          25       0.29   0.14     60     
  BZM            24       0.27   0.20     54     
  1g on ground   MRP2+    10     10.8     4.08   100
  MRPdef         12       6.20   3.08     57     
  noATP          11       7.95   2.25     73     
  BZM            9        9.38   1.59     86     

MRP2+: fully activated MRP2 transporter. MRPdef: MRP-like defective transporter. noATP: without ATP. BZM: Inhibition by benzbromarone. \* Mean E17βG signal in nanograms. ^†^ Percentage of activity.

###### Net E17βG transport activity.

  --------------------------------------------------------------------------
                 Mean\           Dunnett t\   CI 95%          
                 difference \*   *p*                          
  -------------- --------------- ------------ --------------- --------------
  microgravity   MRP2+           0.24         \< 0.001 ^†^    0.14 -- 0.34

  noATP          0.05            0.565        -0.05 -- 0.14   

  BZM            0.02            0.952        -0.08 -- 0.12   

  1g on ground   MRP2+           4.61         0.002 ^†^       1.54 -- 7.69

  noATP          1.75            0.364        -1.25 -- 4.74   

  BZM            3.18            0.049 ^†^    0.01 -- 6.35    
  --------------------------------------------------------------------------

MRP2+: fully activated MRP2 transporter. MRPdef: MRP-like defective transporter. noATP: without ATP. BZM: Inhibition by benzbromarone. CI 95%: confidence interval 95%

\* Mean difference is obtained by subtracting MRPdef signal from the signal detected in each group of samples. Net E17βG transported in nanograms.

Denotes statistically significant

The use of consecutive 2g periods in order to simulate the effects of hypergravity present during a parabolic flight did not show differences in shape, size or number of vesicles between centrifuged vesicles and control samples. Aggregation of vesicles was not observed, neither macroscopically nor microscopically during this simulation. The thermal control system implemented in our prototype maintained the temperature of reaction chambers at 37.25°C (CI 95%: 37.14 -- 37.34°C) during the whole duration of experiments and kept the sample syringe wall temperature below 45°C in preheating chambers in all cases.

###### 

Results from both microgravity and 1g on-ground experiments are presented (labelled \_0g and \_1g). In each gravitational condition four different assays were performed: fully activated transporter or "MRP2+", simple diffusion/control or "MRPdef", ATP-independent transport or "noATP", BZM inhibition assay samples or "BZM".

###### 

Click here for additional data file.

Discussion
==========

To our knowledge, this is the first validation study of a biotechnological approach aimed at evaluating human ABC transporters-mediated active transmembrane transport capabilities in microgravity. Despite the high signal variability expected, the precision attained by our electromechanical system and the enhanced sensibility of the detection protocol used, enabled us to detect net MRP2 transport activity in the short microgravity periods provided by parabolic flights. Furthermore, activation profile and signal levels detected in 1g on ground samples laid within expected commercial standards, confirming the validity of the equipment and procedures used.

The results obtained in microgravity samples showed a significant reduction in MRP2 transport activity, when compared to on ground 1g controls, but presented a comparable activation profile. In order to ensure reliability of these findings, vesicle stability during a parabolic flight was assessed on ground. Simulations revealed that vesicle microscopic structure could remain stable during parabolic manoeuvres, in spite of repeated hypergravity periods. Provided that materials, equipment, procedures and transportation means were equal for all samples in all gravitational conditions, we hypothesized that gravitational stress during parabolic flights may have exerted an effect upon the vesicle membrane or the transporter, preventing proper transport or retention of E17βG. However, such modification should occur at an ultra-structural level, out of reach of our microscopic evaluation. Unfortunately, given the lack of similar research precedents, an ultra-structural evaluation of samples was not planned and was not possible after analysis, since all microgravity samples had been eluted to retrieve E17βG. Therefore, the results of the present evaluation cannot provide a definitive explanation of the effect of microgravity upon ABC transporters-mediated active transmembrane transport. Notwithstanding the aforementioned limitation, we tried to elaborate a plausible hypothesis to explain the present observations.

Compelling evidence indicates that gravity is able to affect cellular and even molecular interactions in numerous life forms, such as in certain protozoa ^[@ref-12],\ [@ref-14]^, bacteria ^[@ref-15]^, plant cells ^[@ref-13],\ [@ref-16],\ [@ref-17]^ or mammals ^[@ref-21]--\ [@ref-23]^. Enzymes from the cell membrane ^[@ref-24]^, cytoskeleton ^[@ref-25]^, cytosol ^[@ref-26]^ and nucleus ^[@ref-24]^ have been found to be sensible to gravitational changes. In principle, gravity is a weaker force compared to intermolecular bonds, polar-apolar interactions and van der Waals forces, therefore it is not clear yet how gravity could affect enzymatic reactions. However, changes in polar-apolar interactions and conformational changes of lipid structures occurring in microgravity could explain some observations ^[@ref-24],\ [@ref-25]^. Structures such as ion channels and trans-membrane signalling systems can be significantly affected by changes in physicochemical properties of the lipid bi-layer cell membrane. Similarly, the mechanism of action of ABC transporters, although still not fully unveiled, is highly dependent on transporter-membrane interactions ^[@ref-28]^, which play a principal role in transporter stabilization and substrate recognition. Interestingly, we were able to demonstrate a reduction of the signal detected in MRPdef controls, where only simple diffusion of substrate was possible. This finding could be explained by an impeded E17βG diffusion into vesicles, or by an increase in membrane permeability in microgravity, which would lead to increased E17βG leakage. In any case, the present observations are indicative of important structural changes in the lipid bi-layer in microgravity, which could be induced by modified polar-apolar interactions of lipid structures in microgravity, as suggested elsewhere ^[@ref-28]^. In this context, the interaction of ABC transporters with the membrane, substrate recognition capabilities and transporter activation could become significantly affected with the potential for relevant biological, physiological and medical consequences in microgravity. However, additional research is required to confirm the present hypothesis.

There are many potential applications of the presented technology, which can benefit both space and terrestrial medicine. Insufficient information exists on drug effects in space ^[@ref-4],\ [@ref-5]^ and is often based in very reduced observational studies ^[@ref-30]^ or in animal models ^[@ref-31]^. While clinical experience throughout spaceflight history has shown no critical metabolic alterations in astronauts, few medications have been studied from a pharmacological point of view in space. A reduction of transmembrane drug transport capabilities in microgravity could lead to drug accumulation and potentially toxic effects during spaceflight. However an increase in membrane permeability would lead to an enhanced drug clearance, increased absorption and significant changes in pharmacological proprieties of drugs. Although not conclusive, our results warrant additional and thorough evaluation of this and other human drug transportation systems in a more stable microgravity platform. To this end, this study describes a new method, based on *in vitro* analysis of human drug transmembrane transport capabilities, by which an approximation to drug effects in microgravity can be made. Similarly, reduced activity of certain ABC transporters has been associated with a number of serious medical conditions on Earth. On the other hand, enhanced activity of ABC transporters can decrease intestinal drug absorption, facilitate hepatic and renal drug excretion, modify drug distribution, and limit drug penetration to certain body tissues. These transporters are known to be responsible for a significant portion of the variability in treatment response to certain drugs used in emergency and critical care medicine ^[@ref-6]--\ [@ref-8]^ and can cause multidrug resistance in a number of solid and hematological neoplasias, where overexpression of certain ABC transporters is present ^[@ref-6],\ [@ref-7]^. Further research derived from this study may help elucidate the intricate mechanism of action of ABC transporters and provide new information for developing more effective treatments for oncology and other medical specialities based on microgravity effects upon these transporters.

There are several limitations in this study. First, we designed a novel electromechanical system to allow the required biochemical reactions to be undertaken precisely and automatically in parabolic flights. This equipment had never been tested before in such conditions. However, results from 1g on ground control samples laid within commercial transport standards, proving functionality and validity of the research equipment and protocols used. Additionally, MRP2 net E17βG transport activity in microgravity fell within the detection range of our enhanced detection method, which confirmed that the required sensitivity was reached. Second, as previously addressed by Macarrone *et al.* ^[@ref-28]^, "microgravity is likely to favour the dispersion in water of less dense molecules such as lipids and the opposite is observed in hypergravity". The contact surface available for ABC transporter exposition to drug-rich medium would be reduced, and transport capability would consequently be diminished, if vesicles precipitated during 2g phases in parabolic flights. Furthermore, vesicle structural integrity has never been evaluated in variable gravitational conditions. Nevertheless, no macroscopic precipitation of samples was observed in-flight due to combined effects of aircraft vibration and the ATP turbulent injection jet. On-ground hypergravity simulation data suggested that vesicles remained stable and did not aggregate after repeated 2g periods. However ultrastructural alterations affecting the membrane or the transporter could still be possible and were not evaluated. Further research should focus on performing a detailed ultra-structural evaluation of vesicles and transporters in a more stable microgravity platform and use whole human cells to provide a more conclusive answer on the potential physiological and clinical effects of our findings. Other factors were also considered as possible disruptors of results and were evaluated. The temperature was strictly maintained within a narrow margin during experiments but aircraft pressure was reduced in flight (800 hPa in flight). However, pressure variations were not expected to cause any modification in sample composition nor in transport activity in our experimental setup.

In conclusion, we validated a new methodology for evaluating ABC transporters activity in microgravity during parabolic flights. Our results demonstrated that despite time constrains, the combination of an adapted commercial assay, a highly accurate electromechanical system and an enhanced drug detection protocol can provide enough accuracy, reproducibility and sensitivity to detect transport activity in microgravity. A significant decrease in transport activity of fully activated samples and a reduction of signal detected in negative controls could be observed in microgravity. While the present results are insufficient for drawing conclusive explanations to these observations, we hypothesize that altered polar-apolar interactions induced by gravitational stress during parabolic manoeuvres affected vesicle's lipid bi-layer membrane, eventually changing its physicochemical properties, limited simple diffusion phenomena and impaired transporter - membrane interaction. However, alternative explanations are possible. Therefore, additional studies will be required to assess membrane and transporter ultra-structures in microgravity, and to confirm these results. The novel methodological approach presented here opens new and interesting research lines in biology, microbiology and human physiology with the potential for significant benefits for both space and terrestrial medicine.

Data availability
=================

Dataset 1. Data of active transmembrane drug transport in microgravity, [10.5256/f1000research.4909.d34169](http://dx.doi.org/10.5256/f1000research.4909.d34169) ^[@ref-32]^

The team of the "ABC transporters in microgravity" project would like to thank all sponsoring partners and supporting institutions, especially IMIM, Fundació CIM, Schneider Electric, Solvo Biotechnology, ESA Education Office and Novespace, and all individual collaborators who have worked in this project.

Appendix
========

Chemical products {#A1}
-----------------

  -----------------------------------------------------------------------------------
  Products used for in-flight operations
  -----------------------------------------------------------------------------------
  1.7M Tris (Tris\[hydroxymethyl\] aminomethane) Water based Dilution

  0.1 M MOPS-Tris (Solution)

  300 mM Glutathione (GSH)

  DMSO. Dimethyl sulfoxide

  7.5 mM E17βG in DMSO

  0.2 M Mg-ATP (ATP, MgCl ~2~, Tris)

  0'1M MgCl ~2~

  0.14 M KCl

  1 M KCl

  7'5 mM Benzbromarone in DMSO

  MRP2 Vesicles

  Assay Mix (solution): 0.1M MOPS-Tri (50% of the solution), 0.14M KCl (50% of the\
  solution), 0.1 MgCl ~2~ (\<1% of the solution)
  -----------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------
  Solutions used for in-flight operations
  -----------------------------------------------------------------------------------
  Washing Mix: 0.1 MOPS-Tris (40% of the solution), 1M KCl (2,5% of the solution),\
  Milli-Q Water (47,5% of the solution)

  Syringes: MRP2/Control vesicles (\<1%) + Assay Mix (97%) + Benzbromarone (1%) +\
  GSH (\<1%) + DMSO (1%) + Estradiol (\<1%)

  Assay Mix (solution): 0.1M MOPS-Tris (50% of the solution), 0.14M KCl (50% of\
  the solution), 0.1 MgCl ~2~ (\<1% of the solution)

  0.2 M Mg-ATP (ATP, MgCl ~2~, Tris)
  -----------------------------------------------------------------------------------

List of components {#A2}
------------------

**[Fluid System]{.ul}**

  -------------------------------------------------------------------------
  Id                     Company   Ref.     Description
  ---------------------- --------- -------- -------------------------------
  Jx                     BD        300910   Reaction syringe (3 ml)

  J1                     BD        300910   Reaction syringe (3 ml)

  J2                     BD        300912   ATP/Assay Mix syringe (60 ml)

  J3                     BD        300865   Washing mix syringe (60 ml)

  J4                     BD        300865   Washing mix syringe (60 ml)

  J5                     BD        300865   Waste syringe (60 ml)

  J6                     BD        300865   Waste syringe (60 ml)

  J7                     BD        300865   Waste syringe (60 ml)

  Anti-leak diaphragm\   BD        385100   Anti-leak valve
  valve                                     

  V1                     BD        394600   3 ways valve

  V2                     BD        394600   3 ways valve

  Tube PVC               BD        397251   PVC line extension
  -------------------------------------------------------------------------

BD: Becton, Dickinson and Company

**[Heating System]{.ul}**

  Id       Company         Ref.              Description
  -------- --------------- ----------------- ------------------------------
  TMP1-8   TC-Direct       410-215           Temperature probe
  R1-4     Minco           HK5407R98.1L12A   Resistance heating
  R5-8     Minco           HK5591R91.4L12A   Resistance heating
           Minco           \#20 TAPE 6FT     Self-fusing silicone tape
  FU1-4    RS components   176-9132          Resettable thermal fuse 84°C
  FU5-8    RS components   176-9148          Resettable thermal fuse 72°C

**[Cooling System]{.ul}**

  -------------------------------------------------------------------------------------
  Id                  Company       Ref.        Description
  ------------------- ------------- ----------- ---------------------------------------
  Polyurethane box    Tecnisample   ISOPUR 13   Contains 1 ATP syringe and 8 Washing\
                                                mix syringes

  Polystyrene box     Tecnisample   N/A         Contains 100 new sample syringes

  Cold Accumulators   Tecnisample   N/A         Rigid plastic water accumulators
  -------------------------------------------------------------------------------------

**[Containment System]{.ul}**

  --------------------------------------------------------------------------------------
  Id                  Company   Ref.               Description
  ------------------- --------- ------------------ -------------------------------------
  PMAFLEX tube        PMA AG    CYLG-48B           Tube which guarantees no leaks\
                                                   and two isolation level\
                                                   between ATP+WB box and\
                                                   polycarbonate sealed box.

  Connector           PMA AG    BVID-M508GT        Accessory to connect PMAFLEX\
                                                   tube with ATP+WB box and\
                                                   polycarbonate sealed box.

  Connector           PMA AG    GMN-M50            Nut of BVID-M508GT

  New syringes box    Peli      0340-001-110-E01   Case with a 67 IP protection level.

  Used syringes box   Peli      1450-001-110-E01   Case with a 67 IP protection level.

  Used filters box    Peli      1450-001-110-E01   Case with a 67 IP protection level.

  ATP+WB box          Peli      0340-001-110-E01   Case with a 67 IP protection level.
  --------------------------------------------------------------------------------------

**[Electrical System]{.ul}**

  -----------------------------------------------------------------------------------
  Id        Company         Ref.              Description
  --------- --------------- ----------------- ---------------------------------------
  QS1       Telemecanique   VCF01             Isolating switch 20A

  QF1       Merlin Guerin   C60N-11933        General breaker switch 2 Phases 7,5A

  F1        Merlin Guerin   ID23523           General dif. switch 2 Phases 25A 30mA

  QF2-14    Merlin Guerin   DPN-21555         Breaker switch 1 Phases 6A

  FA1       Telemecanique   ABL-8FEQ24200     Power unit 20A 24Vdc

  PT1       Telemecanique   XBT-GT4330        Touch screen

  PLC 1     Telemecanique   BMX-XBP0800       Rack 8 positions

            Telemecanique   ABE7 CPA412       Fast connector

            Telemecanique   ABE7 H16R20       Fast connector

            Telemecanique   ABE7 R16T212      Fast connector

            Telemecanique   BMX-CPS2000       Power unit CPU 20W

            Telemecanique   BMX-P342010       CPU

            Telemecanique   BMX-DDI3202       Digital in card

            Telemecanique   BMX-DDO3202       Digital out card

            Telemecanique   BMX-DDO3202       Digital out card

            Telemecanique   BMX-ART0414       Thermocouple input card

            Telemecanique   BMX-ART0414       Thermocouple input card

  SBE       Telemecanique   XB5-AS8445        General Emergency button

  SB1       Telemecanique   XB5-AA42          Push Rearmament

  KA1       Telemecanique   LC1DT20P7         Power relay (220VAC)

  MLIN1     Schneider       SER-36103L75      Linear actuator

  MLIN2     Schneider       SER-36103L75      Linear actuator

  MLIN3     Schneider       SER-36103L75      Linear actuator

  MLIN4     Schneider       SER-36103L75      Linear actuator

  LXM05.1   Schneider       LXM05AD10M2       Servodrivers

  LXM05.2   Schneider       LXM05AD10M2       Servodrivers

  LXM05.3   Schneider       LXM05AD10M2       Servodrivers

  LXM05.4   Schneider       LXM05AD10M2       Servodrivers

  ST1       Schneider       BRS364H           Stepper motor

  CST1      Schneider       SD3 15            Controller stepper motor

  ST2       Schneider       BRS364H           Stepper motor

  CST2      Schneider       SD3 15            Controller stepper motor

  ST3       Schneider       BRS364H           Stepper motor

  CST3      Schneider       SD3 15            Controller stepper motor

  ST4       Schneider       BRS364H           Stepper motor

  CST4      Schneider       SD3 15            Controller stepper motor

  ST5       Schneider       BRS364H           Stepper motor

  CST5      Schneider       SD3 15            Controller stepper motor

  ST6       Schneider       BRS364H           Stepper motor

  CST6      Schneider       SD3 15            Controller stepper motor

  ST7       Schneider       BRS364H           Stepper motor

  CST7      Schneider       SD3 15            Controller stepper motor

  ST8       Schneider       BRS364H           Stepper motor

  CST8      Schneider       SD3 15            Controller stepper motor

  TMP1-8    TC-Direct       408--053          Temperature probe

  R1-4      Minco           HK5407R98.1L12A   Heating resistance

  R5-8      Minco           HK5591R91.4L12A   Heating resistance

  E1-12     Schneider       Xs1N08PA349       Sensors 10A38VCC 2MM

            Weidmüller      WDK 2.5           Terminal block

            Himel           PLA-1573KT        Electrical box

            Himel           PMR157            Electrical plate

            Himel           S27 DL/24         Auxiliar electrical box

            Himel           PF-27             Fixing to auxiliar electrical box

            Himel           IBS 1912/8        Terminal electrical box (\*2)

            Himel           PMDP 2015         Terminal electrical plate (\*2)

  PC        BENQ            R53U-S07-\        Laptop
                            PM740C8UGH6       

            Himel           VF38              Ventilator (Refrigeration unit)

  BTN       Telemecanique   XB4-BW33B5        Green light push button "START"

  BTN       Telemecanique   XB4-BW36B5        Blue light push button "ARM"

  BTN       Telemecanique   XB4-BW35B5        Yellow light push button "STOP"

  BTN       Telemecanique   XB4-BW34B5        Red light push button "HALT"

            PMA             CYLG-29S          Plastic tube

            PMA             BVID-M329GT       Connector tube

            PMA             GMN-M32           Nut

            PMA             SVH-29-010        Clamps

            INTERFLEX       012577            Gland

            INTERFLEX       011277            Gland

            UNEX            60.40.77          Gutters

            UNEX            60.60.77          Gutters

            ILME            CNF16\            Harting connector
                            CNM16             

            ILME            MHO32L\           Harting connector
                            CHI32LS           

            Schneider       DF2 CN08          Fast fuse 8A

            Schneider       DF6 AB10          Carrier fuse

  FU1-4     RS              176-9148          Resettable thermal fuse 84°C

  FU5-8     RS              176-9132          Resettable thermal fuse 72°C

  KA2-9     Finder          Type 40.52        Relays

                                              220V female plug

            RS              327-131           220V male plug
  -----------------------------------------------------------------------------------
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This paper is an interesting contribution to the study of membrane transporter activity in microgravity. The authors discuss in detail the problems not addressed by the study, and important future studies for further validation. This is an excellent addition to the literature, and should be indexed. Introduction was a concise and accurate overview of ABC transporters and microgravity simulations.Good use of controls, including consideration of differential permeability of vesicles themselves due to microgravityNo control with BZM/deformed MPR2 to see differences in noncompetitive inhibition (see if there's activity in negative control vesicles (MRP2def) to see if relevant, particularly for the point about inherent changes in vesicle permeability mentioned in Discussion).Vesicle integrity was confirmed with 2g on-ground simulated flight campaign study (why not just run study at 1g alongside samples to eliminate confounding variables?). Also, is it apparent that the 2g on-ground study truly replicates the experimental flight campaign?Table 2: NoATP mean diference, microgravity, is 0.04, not 0.05 (according to Table 1). Same mistake with 1g on ground MRP2+, though this is most likely due to rounding.Following Table 2's purpose, comparing relative difference (dividing microgravity and 1g mean differences by MRP2def) would have made data more comparable, given stark differences in means presented in Table 1.Data seem to have high variance, despite precision provided by the in-flight device. Comparison of various flight results in groups would hint at potential time-based variance or subtle differences in parabolic flight that could have contributed to these results (repeated flights, to achieve true replicates over pseudoreplicates, could have also aided in this, though may be impractical given predicted high cost of this single flight campaign).No data presented on vesicle integrity outside of discussion in Results; even if not significant, would have been useful.It is not clear that microgravity causes an increase in vesicle permeability given the quite reduced transport of E17BG in microgravity, as suggested in the discussion, though the ratio of E17BG transport in microgravity is higher than that of 1g transport. Future studies looking into this would be useful.More information on parabolic flight campaign would have been useful, not only for reproducibility but given the novelty of this procedure. Studying differential effects of microgravity on mammalian versus insect vesicles would be an important follow-up investigation, as suggested by the authors.
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It is a well written article and deserves to be indexed.

My comments and suggestions are: Abstract should explain the method better, including more details of controls on Earth. It should contain some data (numerical data with the most important statistical analysis)Introduction is good.

Methods Samples and procedures: I suggest explaining the phases of the parabola and their duration. I also believe that it would be good to clarify how many parabolas were used for the tests.Figures are ok, although figure 2 does not add much to the study itself, unless some explanation is added to the figure and its caption.Results I believe that figures could show the microG changes betterIf figures are kept, please correct first line on Table 1 (data is misplaced)I think it should be 1G (not just in results but throughout the text), and then ground should be deleted (it is a pleonasm in this case)Discussion It is very good, clear, and consistentConclusion It could be shortened a bit.It was very good to have considered and presented the limitations of the study.
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